中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

119例艾滋病患者并发药物性肝损伤的临床特点及预后分析

杨君洋 齐唐凯 张仁芳 刘莉 沈银忠 纪永佳 卢洪洲

朱冰, 游绍莉, 万志红, 刘鸿凌, 荣义辉, 臧红, 张爱民, 辛绍杰. HBV相关慢加急性肝衰竭患者血清M30、M65检测及其临床意义[J]. 临床肝胆病杂志, 2013, 29(9): 678-680. DOI: 10.3969/j.issn.1001-5256.2013.09.011.
引用本文: 朱冰, 游绍莉, 万志红, 刘鸿凌, 荣义辉, 臧红, 张爱民, 辛绍杰. HBV相关慢加急性肝衰竭患者血清M30、M65检测及其临床意义[J]. 临床肝胆病杂志, 2013, 29(9): 678-680. DOI: 10.3969/j.issn.1001-5256.2013.09.011.
Zhu Bing, You ShaoLi, Wan ZhiHong, Liu HongLing, Rong YiHui, Zang Hong, Zhang AiMin, Xin ShaoJie. Determination of serum M30 and M65 levels and its clinical significance in patients with HBV- related acute- on-chronic liver failure[J]. J Clin Hepatol, 2013, 29(9): 678-680. DOI: 10.3969/j.issn.1001-5256.2013.09.011.
Citation: Zhu Bing, You ShaoLi, Wan ZhiHong, Liu HongLing, Rong YiHui, Zang Hong, Zhang AiMin, Xin ShaoJie. Determination of serum M30 and M65 levels and its clinical significance in patients with HBV- related acute- on-chronic liver failure[J]. J Clin Hepatol, 2013, 29(9): 678-680. DOI: 10.3969/j.issn.1001-5256.2013.09.011.

119例艾滋病患者并发药物性肝损伤的临床特点及预后分析

DOI: 10.3969/j.issn.1001-5256.2017.08.026
基金项目: 

国家自然科学基金面上项目(81571977); 

详细信息
  • 中图分类号: R512.91;R575

Clinical features and prognosis of AIDS complicated by drug-induced liver injury: an analysis of 119 cases

Research funding: 

 

  • 摘要:

    目的探讨AIDS患者发生药物性肝损伤(DILI)的临床特点及预后。方法收集2014年1月-2015年12月在上海市公共卫生临床中心感染一科确诊为AIDS并符合DILI诊断的患者119例。分析患者用药情况、CD4+T淋巴细胞计数、临床表现、肝脏生化指标、治疗方法、肝损伤持续时间及预后,并对患者DILI进行分型及分级,观察不同药物导致的DILI对肝生化指标的影响。计量资料2组间比较采用Wilcoxon秩和检验,多组间比较采用Kruskal-Wallis H检验;计数资料组间比较采用χ2检验。结果 58例已接受高效抗逆转录病毒治疗患者的肝损伤分级(χ2=15.756,P<0.001)、TBil水平(Z=-3.466,P=0.010)及Alb水平(Z=-1.968,P=0.049)明显高于61例未接受高效抗逆转录病毒治疗的患者;已明确导致患者DILI的药物种类中8例为抗真菌药物、41例为抗细菌药物、18例为抗结核药物、24例为抗病毒药物,抗结核药物较其他3种药物所致DILI患者的TBil水平更高(H=12.804,P=0....

     

  • [1]Drug-induced liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association.Guidelines for the management of drug-induced liver injury[J].J Clin Hepatol, 2015, 31 (11) :1752-1769. (in Chinese) 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志, 2015, 31 (11) :1752-1769.
    [2]KONTORINIS N, TERICH DT.Toxicity of non-nucleoside analogue reverse transcriptase inhibitors[J].Semin Liver Dis, 2003, 23 (2) :173-182.
    [3]RODRIGUEZ-ROSADO R, GARCIA-SAMANIEGO J, SORIANO V.Hepatotoxicity after introduction of highly active antiretroviral therapy[J].AIDS, 1998, 12 (10) :1256.
    [4]CHALASANI NP, HAYASHI PH, BONKOVSKY HL, et al.ACG Clinical Guideline:the diagnosis and management of idiosyncratic drug-induced liver injury[J].Am J Gastroenterol, 2014, 109 (7) :950-966.
    [5]YIMER G, UEDA N, HABTEWOLD A, et al.Pharmacogenetic&pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients[J].PLo S One, 2011, 6 (12) :e27810.
    [6]JONES M, NUNEZ M.Liver toxicity of antiretroviral drugs[J].Semin Liver Dis, 2012, 32 (2) :167-176.
    [7]BJORNSSON ES, BERGMANN OM, BJORNSSON HK, et al.Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland[J].Gastroenterology, 2013, 144 (7) :1419-1425.
    [8]MUGUSI S, NGAIMISI E, JANABI M, et al.Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenzbased HAART with or without tuberculosis co-infection in Tanzania[J].PLo S One, 2012, 7 (7) :e40180.
    [9]WANG YL, QI YW, BAI JS, et al.Clinical analysis of drug induced liver disease in AIDS/HIV patients[J].J Kunming Med Coll, 2009, 30 (3) :129-132. (in Chinese) 汪亚玲, 祁燕伟, 白劲松, 等.AIDS/HIV药物性肝损伤的临床分析[J].昆明医学院学报, 2009, 30 (3) :129-132.
    [10]FERNANDEZ-VILLAR A, SOPENA B, VAZQUEZ R, et al.Isoniazid hepatotoxicity among drug users:the role of hepatitis C[J].Clin Infect Dis, 2003, 36 (3) :293-298.
    [11]COFFIE PA, TONWE-GOLD B, TANON AK, et al.Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women.MTCT-Plus program, Abidjan, C8te d'Ivoire[J].BMC Infect Dis, 2010, 10:188.
    [12]SCHUTZ C, ISMAIL Z, PROXENOS CJ, et al.Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa[J].S Afr Med J, 2012, 102 (6) :506-511.
    [13]TREEPRASERTSUK S, HUNTRAKUL J, RIDTITID W, et al.The predictors of complications in patients with drug-induced liver injury caused by antimicrobial agents[J].Aliment Pharmacol Ther, 2010, 31 (11) :1200-1207.
  • 加载中
计量
  • 文章访问数:  2467
  • HTML全文浏览量:  60
  • PDF下载量:  447
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-01-18
  • 出版日期:  2017-08-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回